Vivo Bio Tech Ltd
Vivo Bio Tech Ltd. engages in the provision of drug development and discovery services. The company is headquartered in Hyderabad, Telangana. The firm offers drug development and discovery services to pharmaceutical and biotech companies across the world. The firm offers services in the areas of In vivo and In vitro toxicity studies, pharmacological investigations, pharmacokinetic and toxicokinetic studies, genotoxicity screening, analytical services, and other. The company provides both regulatory and non-regulatory IND enabling preclinical development services. The company is engaged in screening and evaluating molecules for various pharmacological and therapeutic properties. Specifically for oncology, the Company provides designing and development of syngeneic/xenograft models for evaluation of anti-cancer agents. The firm also customizes In vivo drug metabolism and pharmacokinetics (DMPK) studies to help profile drug candidate in both rodent and non-rodent animal models.
Price Trend & Technical Volume
Daily QuotesPrice Chart (Historical Trend)
Interactive index-style Recharts with entry animations
4V Matrix
Multi-dimensional proprietary scoreValuation Comparison
Intrinsic & Fair Value Multiples* DCF valuation criteria: 2-Stage model: 10% growth rate years 1-5, 10.5% discount rate, 3% terminal growth rate
Community Sentiment
Be the first to voteWhat is your outlook on Vivo Bio Tech Ltd? Anonymous community voting — click an option to cast or update your vote.
AI Diagnostics Score
Weighted model combining fundamental, technical & growth factors.
- Debt/Equity is within safe range (0.72).
- Piotroski financial solvency score: 2/9.
- Momentum metrics indicate consolidation near key averages.
Historical Returns
Growth Analysis
| Metric | 1-Yr YoY | 3-Yr CAGR | 5-Yr CAGR |
|---|---|---|---|
| Sales | +14.3% | +0.7% | +0.6% |
| Profit | -123.5% | — | — |
Institutional Valuation Models & Fundamental Quality Methodology
DesiStocks synthesizes classical institutional valuation models and financial distress frameworks to provide a balanced, multi-dimensional view of Indian equity fundamentals. Review each methodology below to understand its core drivers, appropriate use cases, and inherent assumptions.
Projects operating cash flows minus capital expenditures over a 5-year forecast window, discounted back to present value using the Weighted Average Cost of Capital (WACC). Terminal value assumes a sustainable 4% perpetual growth rate matching India's long-term GDP expansion.
Rooted in classic value investing doctrine: √(22.5 × EPS × Book Value). Graham's formula sets a defensive price ceiling to ensure an investor never pays more than 15x earnings and 1.5x tangible book value simultaneously.
Anchored in Growth at a Reasonable Price (GARP). Equates a fair P/E multiple directly to the sustainable earnings growth rate percentage: Fair Price = EPS × Growth Rate. A PEG below 1.0 signifies potential undervaluation relative to growth.
Nine binary financial tests across profitability (positive ROA, cash flow > net income), balance sheet leverage (declining debt, rising liquidity, zero share dilution), and operational efficiency (improving gross margin and asset turnover). High scores (8–9) confirm robust quality.
Five weighted financial ratios assessing working capital, cumulative profitability, operating leverage, market capitalization, and asset turnover. Proven predictor of balance sheet stress and corporate bankruptcy probability over a 24-month horizon.
Proprietary four-pillar diagnostic framework examining Valuation (multiples vs 5Y history), Value Creation (ROCE spread over WACC cost of capital), Volatility (drawdown containment & beta), and Velocity (operating profit momentum).
All intrinsic valuations and scores are mathematical models generated using publicly available financial statements and historical market disclosures. These calculations do not represent guaranteed future price targets, investment advice, or research analyst buy/sell ratings under SEBI (Research Analysts) Regulations. Always perform independent diligence and consult a licensed financial advisor.